Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 13/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145849 | 1.00 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2EPHX1HTT | |
| SCHEMBL4132285 | 1.00 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2EPHX1HTT | |
| SCHEMBL4135897 | 1.00 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2EPHX1HTT | |
| SCHEMBL4127216 | 1.00 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2EPHX1HTT | |
| SCHEMBL4137645 | 1.00 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2EPHX1HTT | |
| SCHEMBL4132087 | 1.00 | MEN1 (0.58) | MEN1KMT2ASMN1; SMN2EPHX1HTT | |
| SCHEMBL4142888 | 0.94 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2EPHX1HTT | |
| SCHEMBL4141705 | 0.84 | ATM (0.55) | MEN1KMT2AEPHX1HTTALDH1A1 | |
| SCHEMBL4138182 | 0.83 | MAPK14 (0.55) | — | |
| SCHEMBL13772474 | 0.83 | MAPK14 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | MEN1 4659/4885KMT2A 3636/4885SMN1; SMN2 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.